Blackstone Life Sciences made an investment of up to $750 million in Moderna Inc.’s influenza program created with its mRNA technology. The new funding is designed to help propel the program forward and may help bolster a stock that has struggled in the past 12 months.
Shares of Moderna, Inc. (MRNA) are climbing 3% on Wednesday after the company provided an update on regulatory submissions for mRNA-1345, stating that it has submitted marketing authorization applications for mRNA-1345, to the European Medicines Agency, Swissmedic, and the Therapeutic Goods Administration in Australia.